Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation

T. Matsushita, Yoshiki Akatsuka, M. Towatari, K. Takeyama, K. Miyamura, T. Sugihara, S. Minami, Y. Kodera

Research output: Contribution to journalArticle

Abstract

Fifteen adult patients undergoing allogeneic bone marrow transplantation (BMT) received cyclosporine (CSP) as prophylaxis of graft versus host disease (GVHD). In our patients eleven were hematologic malignancies, and four were severe aplastic anemia. Twelve patients were HLA-matched, and three were one locus mismatched. Three patients received CSP only, twelve received CSP and short term methotrexate. Seven patients had acute GVHD, but GVHD over Grade II were seen in only 3 patients who were transplanted from HLA-one locus mismatched donor. 7 patients had chronic GVHD. CSP were given intravenously at 3-5 mg/kg, starting 1 day before BMT. From about day 30, CSP was given orally. CSP concentrations when patients were given orally were lower in patients who had chronic GVHD. Although hypertension and water retention were seen in 8 patients, and renal dysfunction was seen in 3 patients, the side effects of CSP were mild and transient. There were no correlations between serum concentrations and the side effects of CSP. Three patients had the disturbance of hematopoiesis. Ten of fifteen patients are alive at median follow-up of 18.5 months (8-41 months) after BMT.

Original languageEnglish
Pages (from-to)429-436
Number of pages8
Journal[Rinsho ketsueki] The Japanese journal of clinical hematology
Volume30
Issue number4
Publication statusPublished - 01-04-1989
Externally publishedYes

Fingerprint

Homologous Transplantation
Graft vs Host Disease
Bone Marrow Transplantation
Cyclosporine
Aplastic Anemia
Hematopoiesis
Hematologic Neoplasms
Methotrexate
Tissue Donors

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Matsushita, T., Akatsuka, Y., Towatari, M., Takeyama, K., Miyamura, K., Sugihara, T., ... Kodera, Y. (1989). Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation. [Rinsho ketsueki] The Japanese journal of clinical hematology, 30(4), 429-436.
Matsushita, T. ; Akatsuka, Yoshiki ; Towatari, M. ; Takeyama, K. ; Miyamura, K. ; Sugihara, T. ; Minami, S. ; Kodera, Y. / Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation. In: [Rinsho ketsueki] The Japanese journal of clinical hematology. 1989 ; Vol. 30, No. 4. pp. 429-436.
@article{acfbc879911d42309a63d179b8fcedce,
title = "Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation",
abstract = "Fifteen adult patients undergoing allogeneic bone marrow transplantation (BMT) received cyclosporine (CSP) as prophylaxis of graft versus host disease (GVHD). In our patients eleven were hematologic malignancies, and four were severe aplastic anemia. Twelve patients were HLA-matched, and three were one locus mismatched. Three patients received CSP only, twelve received CSP and short term methotrexate. Seven patients had acute GVHD, but GVHD over Grade II were seen in only 3 patients who were transplanted from HLA-one locus mismatched donor. 7 patients had chronic GVHD. CSP were given intravenously at 3-5 mg/kg, starting 1 day before BMT. From about day 30, CSP was given orally. CSP concentrations when patients were given orally were lower in patients who had chronic GVHD. Although hypertension and water retention were seen in 8 patients, and renal dysfunction was seen in 3 patients, the side effects of CSP were mild and transient. There were no correlations between serum concentrations and the side effects of CSP. Three patients had the disturbance of hematopoiesis. Ten of fifteen patients are alive at median follow-up of 18.5 months (8-41 months) after BMT.",
author = "T. Matsushita and Yoshiki Akatsuka and M. Towatari and K. Takeyama and K. Miyamura and T. Sugihara and S. Minami and Y. Kodera",
year = "1989",
month = "4",
day = "1",
language = "English",
volume = "30",
pages = "429--436",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "4",

}

Matsushita, T, Akatsuka, Y, Towatari, M, Takeyama, K, Miyamura, K, Sugihara, T, Minami, S & Kodera, Y 1989, 'Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation', [Rinsho ketsueki] The Japanese journal of clinical hematology, vol. 30, no. 4, pp. 429-436.

Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation. / Matsushita, T.; Akatsuka, Yoshiki; Towatari, M.; Takeyama, K.; Miyamura, K.; Sugihara, T.; Minami, S.; Kodera, Y.

In: [Rinsho ketsueki] The Japanese journal of clinical hematology, Vol. 30, No. 4, 01.04.1989, p. 429-436.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation

AU - Matsushita, T.

AU - Akatsuka, Yoshiki

AU - Towatari, M.

AU - Takeyama, K.

AU - Miyamura, K.

AU - Sugihara, T.

AU - Minami, S.

AU - Kodera, Y.

PY - 1989/4/1

Y1 - 1989/4/1

N2 - Fifteen adult patients undergoing allogeneic bone marrow transplantation (BMT) received cyclosporine (CSP) as prophylaxis of graft versus host disease (GVHD). In our patients eleven were hematologic malignancies, and four were severe aplastic anemia. Twelve patients were HLA-matched, and three were one locus mismatched. Three patients received CSP only, twelve received CSP and short term methotrexate. Seven patients had acute GVHD, but GVHD over Grade II were seen in only 3 patients who were transplanted from HLA-one locus mismatched donor. 7 patients had chronic GVHD. CSP were given intravenously at 3-5 mg/kg, starting 1 day before BMT. From about day 30, CSP was given orally. CSP concentrations when patients were given orally were lower in patients who had chronic GVHD. Although hypertension and water retention were seen in 8 patients, and renal dysfunction was seen in 3 patients, the side effects of CSP were mild and transient. There were no correlations between serum concentrations and the side effects of CSP. Three patients had the disturbance of hematopoiesis. Ten of fifteen patients are alive at median follow-up of 18.5 months (8-41 months) after BMT.

AB - Fifteen adult patients undergoing allogeneic bone marrow transplantation (BMT) received cyclosporine (CSP) as prophylaxis of graft versus host disease (GVHD). In our patients eleven were hematologic malignancies, and four were severe aplastic anemia. Twelve patients were HLA-matched, and three were one locus mismatched. Three patients received CSP only, twelve received CSP and short term methotrexate. Seven patients had acute GVHD, but GVHD over Grade II were seen in only 3 patients who were transplanted from HLA-one locus mismatched donor. 7 patients had chronic GVHD. CSP were given intravenously at 3-5 mg/kg, starting 1 day before BMT. From about day 30, CSP was given orally. CSP concentrations when patients were given orally were lower in patients who had chronic GVHD. Although hypertension and water retention were seen in 8 patients, and renal dysfunction was seen in 3 patients, the side effects of CSP were mild and transient. There were no correlations between serum concentrations and the side effects of CSP. Three patients had the disturbance of hematopoiesis. Ten of fifteen patients are alive at median follow-up of 18.5 months (8-41 months) after BMT.

UR - http://www.scopus.com/inward/record.url?scp=0024644839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024644839&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 429

EP - 436

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 4

ER -